arrow
M

Masashi Hirooka

ehime university
H指数:47
被引数:8,288

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Predictors of long-term changes in mALBI grade in cirrhotic patients after sustained virological response with direct-acting antiviral treatment

直接抗病毒治疗后肝硬化患者mALBI分级长期变化的预测因素

2026-08-250
OAAI
Validation of a pan-ELastography Machine-learning (ELM) score to predict clinically significant portal hypertension in compensated advanced chronic liver disease

验证一种全谱弹性成像机器学习(ELM)评分对代偿期晚期慢性肝病临床显著门静脉高压的预测价值

2026-07-090
OAAI
Sequential metabolic cascade from normal liver to multimorbidity in lean Asian adults: Multistate progression modelling

从正常肝脏到亚洲瘦型多病态的顺序代谢级联:多状态进展建模

2026-07-011
PRE
Diagnostic Impact of Two-Dimensional Shear Wave Elastography for Liver Fibrosis: A Multicenter Retrospective Study

二维剪切波弹性成像对肝纤维化的诊断影响:一项多中心回顾性研究

2026-05-010
OAAI
Clinical Characteristics, Predictive Factors, and the Impact of Antithrombotic Therapy on Bleeding Events in Unresectable Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab

不可切除性肝细胞癌接受阿替利珠单抗联合贝伐珠单抗治疗后出血事件的临床特征、预测因素及抗血栓治疗的影响

2026-04-210
PRE
Impact of Intrahepatic Tumor Burden on Outcomes in Patients With Hepatocellular Carcinoma With Extrahepatic Metastases Treated With Atezolizumab Plus Bevacizumab

肝内肿瘤负荷对接受阿替利珠单抗联合贝伐珠单抗治疗的合并肝外转移的肝细胞癌患者预后的影响

2026-04-100
PRE
Lymphocyte–Monocyte Ratio Predicts the Survival in Patients With HCC Treated With Durvalumab Plus Tremelimumab

淋巴细胞-单核细胞比值预测接受度鲁单单抗联合曲美单抗治疗的HCC患者的生存情况

2026-02-260
PRE
GPAM upregulation enhances hepatic fat deposition and reduces visceral adipose tissue in response to trans-fatty acids

GPAM上调增强了肝脏脂肪沉积,并减少了内脏脂肪组织对反式脂肪酸的响应。

2025-10-040
PRE
Development of a Neural Network to Detect Hepatic Steatosis in Metabolic Dysfunction-Associated Steatotic Liver Disease

Hirooka M,Miyake T,Yano R,Nakamura Y,Okazaki Y,Shimamoto T,等. 开发一种用于检测代谢功能障碍相关脂肪性肝病中肝脂肪变性的神经网络。Gastro Hep Adv. (2025) 5:100765. doi: 10.1016/j.gastha.2025.100765

2025-10-011
OAAI
Clinical Utility of a Prognostic Scoring System Based on LDH and CRP in HCC Patients Receiving Atezolizumab Plus Bevacizumab

基于LDH和CRP的预后评分系统在应用阿替利珠单抗联合贝伐珠单抗治疗的HCC患者中的临床应用价值

2025-09-190
PRE
Efficacy and Safety of Durvalumab Plus Tremelimumab in Hepatocellular Carcinoma Patients With Portal Vein Thrombosis and High Tumor Burden: A Multicenter Retrospective Analysis

度鲁特玛联合特瑞普利单抗在合并门静脉血栓和高肿瘤负荷的肝细胞癌患者中的有效性与安全性:一项多中心回顾性分析

2025-09-060
PRE
Potential role of Geriatric Nutritional Risk Index as a risk factor for immune-mediated adverse events during durvalumab plus tremelimumab therapy in unresectable hepatocellular carcinoma

格瑞特营养风险指数作为不可切除肝癌患者接受度伐利尤单抗联合特瑞普利单抗治疗期间免疫介导不良反应的风险因素的潜在作用

2025-08-200
PRE
Safety and Efficacy of Durvalumab Plus Tremelimumab in Older Individuals With Unresectable Hepatocellular Carcinoma: A Multicenter Analysis

达鲁瓦鲁单抗联合特雷美鲁单抗在不可切除肝细胞癌老年患者中的安全性与有效性:一项多中心分析

2025-08-060
PRE
Early alterations in nutritional indices in metabolic dysfunction-associated steatotic liver disease-related cirrhosis

代谢功能障碍相关脂肪性肝病相关肝硬化的早期营养指标变化

2025-07-160
PRE